Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor

NCT04864821 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteosarcoma
Neuroblastoma
Gastric Cancer
Lung Cancer

Interventions

DRUG: Targeting CD276 CAR T cells

Sponsor

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Collaborators

[object Object]